Data Year:

For its 2024 fiscal year, AMPHASTAR PHARMACEUTICLS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2024
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Mary Luo
Chief Operating Officer, Chief Scientist and Chairman
Total Compensation $3,798,698 View details Pay Rank By Title In Biotechnology industry #3 View more
Rong Zhou
Senior Executive Vice President of Production and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd
Total Compensation $2,127,918 View details Pay Rank By Title In Biotechnology industry #109 View more
William J. Peters
Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director
Total Compensation $2,910,861 View details Pay Rank By Title In Biotechnology industry #159 View more
Jack Yongfeng Zhang
Chief Executive Officer, President, Chief Scientific Office and Director
Total Compensation $7,734,759 View details Pay Rank By Title In Biotechnology industry #152 View more
Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S.
Total Compensation $1,821,762 View details Pay Rank By Title In Biotechnology industry #117 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at AMPHASTAR PHARMACEUTICLS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. AMPHASTAR PHARMACEUTICLS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. AMPHASTAR PHARMACEUTICLS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Mary Luo
Chief Operating Officer, Chief Scientist and Chairman
Total Cash $1,223,761 Equity $2,531,007 Other $43,930 $3,798,698
Rong Zhou
Senior Executive Vice President of Production and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd
Total Cash $915,552 Equity $1,169,005 Other $43,361 $2,127,918
William J. Peters
Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director
Total Cash $1,039,143 Equity $1,815,005 Other $56,713 $2,910,861
Jack Yongfeng Zhang
Chief Executive Officer, President, Chief Scientific Office and Director
Total Cash $1,676,386 Equity $6,004,016 Other $54,357 $7,734,759
Jacob Liawatidewi
Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center and President of Amphastar France Pharmaceuticals, S.A.S.
Total Cash $776,164 Equity $1,004,022 Other $41,576 $1,821,762
For its 2024 fiscal year, AMPHASTAR PHARMACEUTICLS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Jack Yongfeng Zhang CEO Pay $7,734,759 Median Employee Pay $82,289 CEO Pay Ratio 94:1
For its 2024 fiscal year, AMPHASTAR PHARMACEUTICLS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Diane Gerst Total Cash $327,644
Floyd F. Petersen Total Cash $325,003
Gayle Deflin Total Cash $340,003
Howard Lee Total Cash $333,290
Michael A. Zasloff Total Cash $331,003
Richard Prins Total Cash $375,121
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.